Revolution Medicines Inc. (RVMD) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Revolution Medicines Inc. (RVMD) advanced +0.82% to $190.27 as options desks priced 57% call premium vs. 43% put protection around the $186 max-pain magnet. Solid 44% profit margin (-29% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and P
The number of patients actively using Optune Pax in the U.S. declined to 266 at the end of the third quarter, from 285 in the second quarter.
Key TakeawaysNovocure shares fell 5% today, even though third-quarter revenue rose 16% to $193. 4 million and the company raised its 2026 guidance.
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.
Jim Cramer favors Penguin Solutions for its low valuation after strong earnings and says investors should let Revolution Medicines run.
The biotech has experienced a pullback in recent weeks.
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for
Summit, Abivax and Viking have lofty valuations but no FDA-approved products. Each faces a different test of its clinical promise and commercial potential.
LUND, SE / ACCESS Newswire / October 26, 2026 / AB (publ)(STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced the appointment of Monic Stuart, MD, P
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RVMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RVMD. Explore sector supply chains on /butterfly.
Why RVMD Stock advanced +0.82% Today — RQD Quant Desk Flash. Solid 44% profit margin (-29% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.